Why the study?
Does oral administration of novel peptidomimetic renin inhibitors (compound 38a) reduce mean arterial blood pressure in sodium-depleted marmosets?
Population
Sodium-depleted marmosets and in vitro human renin models
Design
Preclinical
Follow-up
up to 8 h post-dose
Authors
Loading...
Supports preclinical development of oral renin inhibitors; leaves open translation to human hypertension.
Does oral administration of novel peptidomimetic renin inhibitors (compound 38a) reduce mean arterial blood pressure in sodium-depleted marmosets?
Novel peptidomimetic renin inhibitors, particularly compound 38a, demonstrate potent in vitro activity and oral efficacy in reducing blood pressure in a marmoset model.
Göschke et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: